Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYAI Dyadic International	$0.75 -6.5%	$0.97	$0.71 ▼ $2.20	$27.08M	0.89	246,708 shs	179,577 shs
IKT Inhibikase Therapeutics	$1.75 +2.3%	$1.79	$1.12 ▼ $4.20	$130.10M	0.9	194,830 shs	143,575 shs
SCLX Scilex	$18.08 +4.1%	$9.35	$3.60 ▼ $46.20	$125.76M	1.32	306,474 shs	540,402 shs
SKYE Skye Bioscience	$3.51 +7.3%	$3.55	$1.14 ▼ $7.47	$108.77M	2.21	349,716 shs	394,378 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYAI Dyadic International	0.00%	-20.14%	-23.64%	-28.05%	-44.16%
IKT Inhibikase Therapeutics	0.00%	+22.38%	-7.89%	-12.94%	+34.62%
SCLX Scilex	0.00%	+15.01%	+95.46%	+329.45%	-58.67%
SKYE Skye Bioscience	0.00%	-0.28%	-5.65%	+87.20%	-22.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DYAI Dyadic International	3.3871 of 5 stars	3.5	5.0	2.4	3.3	0.0
IKT Inhibikase Therapeutics	2.0438 of 5 stars	3.3	2.0	2.1	0.0	1.3
SCLX Scilex	2.1953 of 5 stars	3.3	2.0	2.2	1.7	0.6
SKYE Skye Bioscience	1.9179 of 5 stars	3.6	2.0	3.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYAI Dyadic International	3.00	Buy	$6.00	701.82% Upside
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	271.43% Upside
SCLX Scilex	2.50	Moderate Buy	$455.00	2,416.59% Upside
SKYE Skye Bioscience	3.14	Buy	$15.50	341.60% Upside

Current Analyst Ratings Breakdown

Latest DYAI, IKT, SCLX, and SKYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2025	SKYE Skye Bioscience	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
6/24/2025	SKYE Skye Bioscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYAI Dyadic International	$3.49M	7.76	N/A	N/A	($0.01) per share	-74.83
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
SCLX Scilex	$44.24M	2.84	N/A	N/A	($35.80) per share	-0.51
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$1.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYAI Dyadic International	-$5.81M	-$0.19	N/A	N/A	N/A	-134.84%	-355.39%	-60.66%	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
SCLX Scilex	-$72.81M	-$29.02	N/A	N/A	N/A	-179.12%	N/A	-109.95%	N/A
SKYE Skye Bioscience	-$26.57M	-$1.06	N/A	N/A	N/A	N/A	-76.03%	-69.20%	N/A

Latest DYAI, IKT, SCLX, and SKYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	DYAI Dyadic International	-$0.06	-$0.06	N/A	-$0.06	$0.60 million	$0.97 million
8/13/2025	Q2 2025	SCLX Scilex	-$4.55	-$7.42	-$2.87	-$7.42	$26.25 million	$9.90 million
8/7/2025	Q2 2025	SKYE Skye Bioscience	-$0.34	-$0.44	-$0.10	-$0.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYAI Dyadic International	5.40	2.02	3.98
IKT Inhibikase Therapeutics	N/A	0.85	0.85
SCLX Scilex	N/A	0.11	0.09
SKYE Skye Bioscience	N/A	6.09	11.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYAI Dyadic International	27.95%
IKT Inhibikase Therapeutics	3.81%
SCLX Scilex	69.67%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
DYAI Dyadic International	29.50%
IKT Inhibikase Therapeutics	7.30%
SCLX Scilex	7.94%
SKYE Skye Bioscience	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYAI Dyadic International	7	36.19 million	25.51 million	Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
SCLX Scilex	80	6.96 million	6.40 million	Optionable
SKYE Skye Bioscience	11	30.99 million	29.59 million	Optionable

DYAI, IKT, SCLX, and SKYE Headlines

Recent News About These Companies

Skye Bioscience (NASDAQ:SKYE) Raised to "Strong-Buy" at Evercore ISI

August 17 at 2:26 AM | americanbankingnews.com

Evercore ISI Group Initiates Coverage of Skye Bioscience (SKYE) with Outperform Recommendation

August 16 at 1:30 PM | msn.com

Evercore starts Skye Bioscience at Outperform on nimacimab potential

August 14 at 12:13 AM | msn.com

Skye Bioscience initiated with an Outperform at Evercore ISI

August 14 at 12:13 AM | msn.com

Skye Bioscience, Inc. (NASDAQ:SKYE) is Altium Capital Management LLC's 9th Largest Position

August 14 at 7:31 AM | marketbeat.com

Skye Bioscience Earnings Call: Positive Outlook Amid Challenges

August 13, 2025 | msn.com

Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform

August 9, 2025 | msn.com

Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ...

August 9, 2025 | finance.yahoo.com

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

August 7, 2025 | globenewswire.com

We Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth Carefully

August 6, 2025 | finance.yahoo.com

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

July 30, 2025 | globenewswire.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by Analysts

July 28, 2025 | marketbeat.com

Skye Bioscience (NASDAQ:SKYE) Shares Down 8% - What's Next?

July 25, 2025 | marketbeat.com

SKYE Stock Price Quote | Morningstar

July 11, 2025 | morningstar.comM

Skye Bioscience, Inc. (SKYE) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

Skye Bioscience Highlights Nimacimab’s Promise in Obesity Treatment, Anticipates Phase 2a Data

July 6, 2025 | msn.com

Positive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past year

June 25, 2025 | finance.yahoo.com

Skye Bioscience Shares Nimacimab "Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th ...

June 24, 2025 | manilatimes.netM

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes ... - Morningstar

June 24, 2025 | morningstar.comM

Skye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment - Nasdaq

June 24, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI, IKT, SCLX, and SKYE Company Descriptions

Dyadic International NASDAQ:DYAI

$0.75 -0.05 (-6.46%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$0.79 +0.04 (+5.57%)

As of 08/15/2025 06:20 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Inhibikase Therapeutics NYSE:IKT

$1.75 +0.04 (+2.34%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.75 0.00 (0.00%)

As of 08/15/2025 04:10 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Scilex NASDAQ:SCLX

$18.08 +0.71 (+4.09%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$18.42 +0.34 (+1.85%)

As of 08/15/2025 07:59 PM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Skye Bioscience NASDAQ:SKYE

$3.51 +0.24 (+7.34%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.50 0.00 (-0.14%)

As of 08/15/2025 07:56 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time